FAQs and Guidances

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Federal government:

Professional societies:

  • American Society of Clinical Oncology FAQ: Emerging issues and challenges in caring for patients with cancer during the coronavirus pandemic

  • American Association for Cancer Research FAQ: Information on virtual annual meetings

  • American Cancer Society FAQ: Common questions about the new coronavirus outbreak

  • Society for Immunotherapy of Cancer Resources: Patient management and basic and translational research

  • Community Oncology Alliance resources: Coronavirus (COVID-19) practice resources and protocols

  • Leukemia & Lymphoma Society FAQ: Resources and what you should know about the coronavirus

  • American Society for Radiation Oncology FAQ: COVID-19 recommendations and information

  • American College of Surgeons resources: For the surgical community

  • Society for Immunotherapy of Cancer resources: Implications for patients, translational research

  • GO2 Foundation for Lung Cancer resources

  • American Society for Transplantation and Cellular Therapy resources

  • European Blood and Marrow Transplantation Society recommendations

  • World Marrow Donor Association resources

  • National Institute for Health Care Management Foundation resources

Research centers:

  • St. Jude Children’s Research Hospital FAQ: COVID-19 and children with cancer

  • Journal of the National Comprehensive Cancer Network: How to manage cancer care during COVID-19 pandemic

Companies:

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login